Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19284312 | ANTIGEN-BINDING PROTEINS AND RELATED METHODS OF USE | July 2025 | February 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19081458 | PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 18989801 | Anti-PD-1 Antibodies and Fusion Proteins | December 2024 | November 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18807097 | METHODS OF MANUFACTURING DIMERIC ANTIBODIES | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18154761 | ANTI-CCR8 ANTIBODIES | January 2023 | March 2026 | Allow | 38 | 0 | 0 | Yes | No |
| 18011878 | Anti-PD-1 Antibodies and Fusion Proteins | December 2022 | October 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18060135 | CD38 MODULATING ANTIBODY | November 2022 | January 2025 | Allow | 26 | 1 | 0 | No | No |
| 18053868 | CD20-PD1 BINDING MOLECULES AND METHODS OF USE THEREOF | November 2022 | October 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17953930 | LUNG-TARGETING SINGLE-DOMAIN ANTIBODIES AND PURIFICATION METHODS | September 2022 | June 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17933954 | HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES | September 2022 | May 2025 | Allow | 31 | 1 | 1 | Yes | No |
| 17906718 | GPC3 CAR- T CELL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17932178 | METHOD FOR IMPROVING AFFINITY OF ANTI-CYTOKINE ANTIBODY FOR ANTIGEN, METHOD FOR PRODUCING ANTI-CYTOKINE ANTIBODY, AND ANTI-CYTOKINE ANTIBODY | September 2022 | July 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17904057 | CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN AND USE THEREOF | August 2022 | March 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17861179 | SYNTHETIC IL-7 AND IL-7 IMMUNOCYTOKINES | July 2022 | September 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17698889 | CHIMERIC CELLS COMPRISING DENDRITIC CELLS AND ENDOTHELIAL CELLS RESEMBLING TUMOR ENDOTHELIUM | March 2022 | April 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17686261 | Dimeric Antigen Receptors (DAR) that Bind BCMA | March 2022 | February 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17676654 | TREATING MYELOMAS | February 2022 | February 2026 | Abandon | 48 | 1 | 0 | No | No |
| 17588086 | BISPECIFIC ANTI LRRC15 AND CD3EPSILON ANTIBODIES | January 2022 | March 2026 | Abandon | 49 | 1 | 0 | No | No |
| 17631075 | T CELL RECEPTOR FOR RECOGNIZING SSX2 ANTIGEN SHORT PEPTIDE | January 2022 | January 2026 | Allow | 48 | 1 | 0 | No | No |
| 17586652 | ENGINEERED HIGH-AFFINITY HUMAN T CELL RECEPTORS | January 2022 | November 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17618747 | COMPOSITIONS AND METHODS FOR TREATING CANCER | December 2021 | February 2026 | Abandon | 50 | 1 | 0 | No | No |
| 17536663 | CCL20 AS A PREDICTOR OF CLINICAL RESPONSE TO IL23-ANTAGONISTS | November 2021 | January 2026 | Abandon | 49 | 1 | 0 | No | No |
| 17613632 | METHOD OF PROVIDING SAFE ADMINISTRATION OF AN ANTI-CD40 ANTIBODY | November 2021 | December 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17611551 | ANTIBODY AGAINST CLAUDIN 18A2 AND USE THEREOF | November 2021 | July 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17611231 | METHOD TO TREAT TYPE 2 INFLAMMATION OR MAST-CELL DEPENDENT DISEASE | November 2021 | December 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17611054 | EPCAM BINDING PROTEINS AND METHODS OF USE | November 2021 | April 2025 | Allow | 42 | 0 | 0 | Yes | No |
| 17608738 | CLL-1 TARGETED IMMUNOTHERAPIES | November 2021 | May 2025 | Allow | 43 | 1 | 0 | No | No |
| 17512961 | COMBINATION THERAPIES | October 2021 | August 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17606103 | Rank Pathway Inhibitors in Combination with CDK Inhibitors | October 2021 | August 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17507531 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17605290 | ENGINEERED CELLS AND USES THEREOF | October 2021 | September 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17594532 | ANTIBODY FORMULATION | October 2021 | October 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17604555 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | October 2021 | May 2025 | Allow | 43 | 1 | 0 | No | No |
| 17604505 | BIOASSAY FOR T-CELL CO-STIMULATORY PROTEINS CONTAINING FC DOMAINS | October 2021 | November 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17603761 | ANTI AQP3 MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17603444 | DAF-MCP CHIMERIC PROTEINS, PROCESS TO MANUFACTURE THE SAME AND USE OF THE CHIMERIC PROTEIN FOR TREATING PATHOLOGICAL CONDITIONS INVOLVING THE COMPLEMENT SYSTEM | October 2021 | February 2026 | Allow | 52 | 2 | 0 | Yes | No |
| 17600893 | HIV/HCV CROSS-REACTIVE ANTIBODIES AND USES THEREOF | October 2021 | September 2025 | Allow | 48 | 1 | 1 | No | No |
| 17600095 | METHODS AND COMPOSITIONS INVOLVING CHIMERIC BINDING POLYPEPTIDES | September 2021 | September 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17599377 | Engineered Variant Antibodies that Bind CD38 | September 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17441519 | GLYPICAN-3 (GPC-3) ANTIBODIES | September 2021 | April 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17439974 | FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF | September 2021 | September 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17436936 | T CELL RECEPTORS AND METHODS OF USE THEREOF | September 2021 | October 2025 | Allow | 50 | 0 | 1 | Yes | No |
| 17310957 | ANTI-FXI/FXIA ANTIBODY AND USE THEREOF | September 2021 | December 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17298817 | ANTI-HUMAN TIM-3 MONOCLONAL ANTIBODY AND APPLICATION THEREOF | August 2021 | September 2025 | Abandon | 52 | 1 | 0 | No | No |
| 17403406 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | August 2021 | March 2025 | Allow | 43 | 1 | 1 | No | No |
| 17430540 | CANCER IMMUNOTHERAPY USING COMBINATIONS OF CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND MONOCLONAL ANTIBODIES | August 2021 | January 2026 | Abandon | 53 | 2 | 1 | No | No |
| 17399729 | Activatable Anti-CTLA-4 Antibodies and Uses Thereof | August 2021 | June 2025 | Allow | 46 | 1 | 1 | No | No |
| 17429672 | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) INHIBITORY ANTIBODY AND USES THEREOF | August 2021 | February 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17331768 | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains | May 2021 | March 2025 | Allow | 46 | 1 | 0 | Yes | No |
| 17058889 | POLYPEPTIDE COMPRISING IL-1R1 BINDING DOMAIN AND CARRYING MOIETY | November 2020 | September 2025 | Abandon | 58 | 2 | 1 | No | No |
| 16867296 | COMBINATION TUMOR IMMUNOTHERAPY | May 2020 | December 2025 | Abandon | 60 | 5 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner HECK, BRYAN WILLIAM works in Art Unit 1643 and has examined 31 patent applications in our dataset. With an allowance rate of 45.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner HECK, BRYAN WILLIAM's allowance rate of 45.2% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HECK, BRYAN WILLIAM receive 1.13 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HECK, BRYAN WILLIAM is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +77.3% benefit to allowance rate for applications examined by HECK, BRYAN WILLIAM. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 40.0% of applications are subsequently allowed. This success rate is in the 90% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 14.3% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.